Nemozolol, 400 mg 5 pcs

Pharmacotherapeutic group:

Anthelminthic and antiprotozoal agents.

ATX code: P02CA03

Pharmacological properties

Pharmacodynamics

Albendazole is an anthelmintic drug, the pharmacological properties of which are due to the action of the active substance – albendazole. Albendazole belongs to the group of carbamate benzimidazoles. The mechanism of action of albendazole is its ability to disrupt the activity of microtubular system of cells of the intestinal canal of helminthes, causing damage to tubulin protein. A consequence of this is biochemical disorders in the cell – inhibition of glucose transport and fumaratreductase, which underlies the suppression of cell division at the metaphase stage and which is associated with inhibition of oviposition and development of helminth larvae. Albendazole blocks movement of secretory granules and other organelles in muscle cells of roundworms, causing their death.

Albendazole is effective against most intestinal nematodes and larval (larval stages) of cestodes as well as giardia. Albendazole as an antiparasitic drug has a fairly broad spectrum of action.

Pharmacokinetics

Absorption. After oral administration the drug is poorly absorbed in gastrointestinal tract and is not determined in unchanged form in blood plasma. Bioavailability is low when taken orally. Fatty food increases absorption and maximum concentration by 5 times.

Metabolism. Albendazole is rapidly converted in the liver to the primary metabolite – albendazole sulfoxide, which also has anthelmintic activity.

Distribution. Maximum plasma concentration of albendazole sulfoxide is reached 2-5 hours after administration. By 70% metabolite is bound to plasma proteins and completely distributed throughout the body: detected in urine, bile, liver, in the wall and fluid of helminth cysts, cerebrospinal fluid.

Extraction. Albendazole sulfoxide in the liver is converted into albendazole sulfone (secondary metabolite) and other oxidized products. Half-life of albendazole sulfoxide is 8-12 hours. It is excreted through the kidneys in the form of various metabolites. Excretion of albendazole and albendazole sulfoxide through the kidneys is insignificant. Clearance does not change in patients with impaired renal function.

In patients with liver damage – bioavailability is increased, maximum concentration of albendazole sulfoxide in blood plasma is increased by 2 times, and the half-life is prolonged.

Albendazole induces cytochrome SUR1A2 in human liver cells and accelerates metabolism of many drugs.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Similarities